Clinical trials: Antipsychotic
Schizophrenia
Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)
The purpose of this study is to determine whether MK-8435 (Org 25935) is more effective than placebo in improving negative symptoms in participants with schizophrenia who are concurrently treated with a stable dose of a second…
- Trial name
- GIANT (NCT00725075)
- Testing
- MK-8435 (Org 25935) 4-8 mg, MK-8435 (Org 25935) 12-16 mg
- Volunteers
- 215 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia.
- Trial name
- NCT00097942
- Testing
- memantine HCl
- Where
- 13 sites in United States
- Volunteers
- 138 people
- Sponsor
- Forest Laboratories
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01714661
- Testing
- EVP-6124
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 753 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Schizoaffective Disorder
Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
Because ziprasidone has not been extensively studied and is not widely accepted in the severely mentally ill in State hospitals this study aims to demonstrate its effectiveness and relative lack of side effects.
- Trial name
- NCT00458211
- Testing
- ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bronx Psychiatric Center
Schizophrenia
Long-term Study of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
- Trial name
- NCT01104792
- Testing
- Cariprazine
- Where
- 86 sites in United States, Colombia and 4 more
- Volunteers
- 752 people
- Sponsor
- Forest Laboratories
Schizophrenia
An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia
This multi-centre study will evaluate the safety and related factors study of atypical antipsychotics long-term treatment in Chinese Patients with Schizophrenia.
- Trial name
- NCT02640911
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizoaffective Disorder
The Effects of Aripiprazole on Patients With Metabolic Syndrome
The primary goal of this study is to assess the effect of aripiprazole on patients who developed metabolic syndrome while taking other second generation antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- NCT00224822
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- New Mexico VA Healthcare System
Autism Spectrum Disorder
Weight Management Intervention for Youth and Young Adults With Autism Spectrum Disorder
Psychotropic medications are the first-line treatment across several diagnostic categories encompassing severe mood disturbances and behavioral problems.
- Trial name
- ACORN-ASD (NCT03865719)
- Testing
- Healthy Habits for Life
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
Schizophrenia
New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia
The purpose of this study is to: 1. Evaluate the efficacy and safety of the new antipsychotics, quetiapine (300-500mg/day) and risperidone (3-4mg/day) compared to each other and to fluphenazine (10-15mg/day), a high potency…
- Trial name
- NCT00161018
- Testing
- Quetiapine, Risperidone, Fluphenazine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
The purpose of this study is to determine if adding extended-release galantamine hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well tolerated and effective in improving cognitive…
- Trial name
- NCT00077727
- Testing
- Extended-release galantamine hydrobromide
- Volunteers
- 107 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
Background: Among individuals with schizophrenia, there is an increased prevalence of obesity, dyslipidemia ,diabetes mellitus and related conditions such as cardiovascular disease.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01215383
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Severe Mental Disorder, Metabolic Complication
Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic
This study will examine the effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness
- Conditions
- Severe Mental Disorder, Metabolic Complication, Side-Effect;Medication, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT06624462
- Testing
- Treatment in the Meta Care Clinic, Standard care with general practitioner and/or outpatient clinics
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Bjorn H. Ebdrup
Psychotropic Drugs, Psychiatric Drugs
Decreasing Harms and Improving Child Health
The investigators are doing this study because they know from research and talking with caregivers that kids can be on a bunch of medications, and it's hard to keep track of what the medications are for and whether or not they…
- Conditions
- Psychotropic Drugs, Psychiatric Drugs, Children, Shared Decision Making
- Trial name
- NCT07392489
- Testing
- AWARE Shared Decision Making Medication Review
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Glyn Jones-Elwyn
Schizophrenia
Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
The purpose of this study is to assess the 14-day and 12-week safety and efficacy of Depakote ER used in combination with either olanzapine or risperidone versus antipsychotic monotherapy with olanzapine or risperidone for the…
- Trial name
- NCT00073164
- Testing
- Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
- Where
- 35 sites in United States
- Volunteers
- 400 people
- Sponsor
- Abbott
Metabolic Syndrome
Antipsychotics and Metabolic Syndrome
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and quality of life.
- Trial name
- NCT00636753
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Schizophrenia
Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch
Nautralsitic, Open-label, Single Arm, Uncontrolled Study Evaluating the Effects of Long Acting Injectable (LAI) on Phychosocial Functioning Congitive Functioning and Patient Reported Acceptability of Treatment 'Reported…
- Trial name
- ARILAI (NCT02697045)
- Testing
- Aripiprazole 400mg LAI
- Where
- 15 sites in Turkey (Türkiye)
- Volunteers
- 23 people
- Sponsor
- Abdi İbrahim Otsuka
Schizophrenia, Schizoaffective Disorder
A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses
An individual's genetic make-up is known to determine their response to antipsychotic medication. Genetic markers that determine efficacy and side effects of medication may be identified and used to predict treatment outcome.
- Trial name
- NCT00701753
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- TheraGenetics Limited
Schizophrenia
Bexarotene Treatment in Schizophrenia
In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) on severity of psychopathology, cognitive…
- Trial name
- NCT00141947
- Testing
- bexarotene (Targretin)
- Where
- 2 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Beersheva Mental Health Center